Erika Cecchin

List of Publications by Citations

87 papers	2,168 citations	22 h-index	43 g-index
100 ext. papers	2,797 ext. citations	5.4 avg, IF	4.83 L-index

#	Paper	IF	Citations
87	The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, **2006**, 24, 3061-8	2.2	280
86	Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. *Journal of Clinical Oncology*, **2009**, 27, 2457-65	2.2	183
85	Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. *Clinical Pharmacology and Therapeutics*, **2017**, 101, 341-358	6.1	157
84	Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, **2010**, 28, 866-71	2.2	128
83	Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. *Lancet Oncology, The*, **2016**, 17, 1137-1146	21.7	82
82	A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. *Pharmacogenomics Journal*, **2013**, 13, 403-9	3.5	57
81	Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. *Drug Resistance Updates*, **2015**, 20, 39-70	23.2	56
80	Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. *Clinical Cancer Research*, **2009**, 15, 3550-6	12.9	56
79	Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. *Pharmacogenomics Journal*, **2011**, 11, 214-26	3.5	54
78	Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. *International Journal of Cancer*, **2015**, 137, 2971-80	7.5	48
77	Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. *Journal of Pharmacology and Experimental Therapeutics*, **2013**, 345, 95-101	4.7	43
76	Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. *World Journal of Gastroenterology*, **2019**, 25, 3870-3896	5.6	40
75	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. *Pharmacogenetics and Genomics*, **2013**, 23, 549-57	1.9	38
74	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. *Drug Resistance Updates*, **2020**, 51, 100702	23.2	32
73	Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. *Clinical Cancer Research*, **2005**, 11, 6901-7	12.9	32
72	Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. *PLoS ONE*, **2014**, 9, e84940	3.7	28
71	Pharmacogenetics of irinotecan. *Anti-Cancer Agents in Medicinal Chemistry*, **2003**, 3, 225-37		27

70	ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. *Pharmacogenetics and Genomics*, **2015**, 25, 573-83	1.9	25
69	MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer. *Tumor Biology*, **2010**, 31, 23-32	2.9	25
68	Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. *Clinical Pharmacology and Therapeutics*, **2017**, 102, 123-130	6.1	23
67	Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice. *Current Pharmaceutical Biotechnology*, **2017**, 18, 204-209	2.6	22
66	Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. *BMC Cancer*, **2004**, 4, 11	4.8	22
65	HLA-G 3RUTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment. *PLoS ONE*, **2015**, 10, e0144000	3.7	22
64	SNCA 3RUTR genetic variants in patients with ParkinsonR disease and REM sleep behavior disorder. *Neurological Sciences*, **2017**, 38, 1233-1240	3.5	21
63	Predictive response biomarkers in rectal cancer neoadjuvant treatment. *Frontiers in Bioscience - Scholar*, **2014**, 6, 110-9	2.4	21
62	Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve PatientsRManagement and Therapy Outcomes. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	20
61	miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?. *Pharmacogenomics*, **2012**, 13, 1635-50	2.6	20
60	New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. *Cells*, **2019**, 8,	7.9	19
59	Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	19
58	UGT1A1*28 polymorphism in ovarian cancer patients. *Oncology Reports*, **2004**, 12, 457-62	3.5	19
57	Genetic biomarkers for hepatocellular cancer risk in a caucasian population. *World Journal of Gastroenterology*, **2017**, 23, 6674-6684	5.6	18
56	Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity. *American Journal of Human Genetics*, **2019**, 104, 1158-1168	11	17
55	Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis. *Vaccines*, **2021**, 9,	5.3	17
54	The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 994-1002	6.1	17
53	MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. *Pharmacogenomics Journal*, **2015**, 15, 219-25	3.5	16

52	Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine. *Pharmacogenomics*, **2016**, 17, 1547-71	2.6	16
51	Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. *Drug Resistance Updates*, **2018**, 39, 18-40	23.2	16
50	A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. *International Journal of Biological Markers*, **2014**, 29, e310-6	2.8	16
49	Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase. *International Journal of Biological Markers*, **2003**, 18, 218-21	2.8	16
48	UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. *Liver International*, **2017**, 37, 1345-1353	7.9	14
47	Nuclear receptors and drug metabolism for the personalization of cancer therapy. *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 291-306	5.5	14
46	Pharmacogenetics and stomach cancer: an update. *Pharmacogenomics*, **2007**, 8, 497-505	2.6	14
45	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	14
44	Association of the HLA-G 3'UTR polymorphisms with colorectal cancer in Italy: a first insight. *International Journal of Immunogenetics*, **2016**, 43, 32-9	2.3	14
43	Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia. *Sexual Medicine*, **2017**, 5, e61-e71	2.7	13
42	Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?. *Pharmacogenomics*, **2013**, 14, 2035-54	2.6	13
41	Decision criteria for rational selection of homogeneous genotyping platforms for pharmacogenomics testing in clinical diagnostics. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 447-59	5.9	12
40	A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients. *Pharmacogenomics Journal*, **2015**, 15, 513-20	3.5	11
39	Association of -3 rs1053004 and rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. *Frontiers in Pharmacology*, **2018**, 9, 367	5.6	11
38	Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. *Oncotarget*, **2016**, 7, 19781-93	5.3	11
37	Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy. *Current Medicinal Chemistry*, **2020**, 27, 4249-4273	4.3	10
36	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. *Pharmacogenetics and Genomics*, **2020**, 30, 131-144	1.9	10
35	Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	10

34	HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	9
33	Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. *Frontiers in Pharmacology*, **2017**, 8, 712	5.6	8
32	Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. *Scientific Reports*, **2019**, 9, 13008	4.9	7
31	BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress. *Cell Death and Disease*, **2016**, 7, e2374	9.8	7
30	Identification of Novel Somatic Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). *International Journal of Molecular Sciences*, **2018**, 19,	6.3	6
29	Educating the Next Generation of Pharmacogenomics Experts: Global Educational Needs and Concepts. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 313-316	6.1	6
28	Pharmacogenomics and stomach cancer. *Pharmacogenomics*, **2004**, 5, 627-41	2.6	6
27	Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer. *Oncotarget*, **2017**, 8, 22863-22875	3.3	6
26	miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway. *Cancer Chemotherapy and Pharmacology*, **2020**, 86, 361-374	3.5	6
25	Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. *Frontiers in Oncology*, **2019**, 9, 1312	5.3	6
24	FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy. *Genes*, **2019**, 10,	4.2	5
23	Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib. *Frontiers in Pharmacology*, **2020**, 11, 36	5.6	5
22	UGT1A1*28 polymorphism in ovarian cancer patients. *Oncology Reports*,	3.5	5
21	Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers. *European Journal of Cancer*, **2018**, 104, 210-218	7.5	5
20	Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. *Genes*, **2019**, 10,	4.2	4
19	Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants. *Genes*, **2019**, 10,	4.2	4
18	Immunogenetic markers in IL17F predict the risk of metastases spread and overall survival in rectal cancer patients treated with neoadjuvant chemoradiotherapy. *Radiotherapy and Oncology*, **2020**, 149, 30-37	5.3	4
17	Clinical implications of genetic polymorphisms on stomach cancer drug therapy. *Pharmacogenomics Journal*, **2007**, 7, 76-80	3.5	4

16	A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study. *Clinical Breast Cancer*, **2019**, 19, 137-145.e4	3	4
15	A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. *Frontiers in Pharmacology*, **2018**, 9, 1101	5.6	4
14	Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy.. *Cell Death and Disease*, **2022**, 13, 398	9.8	4
13	Clonal Evolution of c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC). *Cells*, **2019**, 8,	7.9	3
12	rs4143815-, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	3
11	Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. *Frontiers in Pharmacology*, **2020**, 11, 897	5.6	3
10	Genetic Variants of the Gene, Telomere Length, and Circulating as Prognostic Markers in Rectal Cancer Patients. *Cancers*, **2020**, 12,	6.6	2
9	Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. *Pharmacogenomics*, **2019**, 20, 1179-1187	2.6	2
8	A TGF-associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. *Gynecologic Oncology*, **2020**, 156, 233-242	4.9	2
7	The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines. **2019**, 2, 116-130		1
6	Pharmacogenetics of stomach cancer. *I Supplementi Di Tumori*, **2003**, 2, S19-22		1
5	SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy.. *Frontiers in Pharmacology*, **2021**, 12, 778781	5.6	1
4	Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients. *AAPS Journal*, **2020**, 22, 59	3.7	0
3	Reply to the Letter to the Editor from Chowbay et al. *Clinical Cancer Research*, **2006**, 12, 1942.2-1942	12.9	
2	Pharmacogenetics in Cancer Management: Scenario for Tailored Therapy **2008**, 389-403		
1	Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. *Pharmacogenomics*, **2020**, 21, 995-1010	2.6	